Anzeige
Mehr »
Login
Sonntag, 23.02.2025 Börsentäglich über 12.000 News von 688 internationalen Medien
851 % Rendite in 30 Tagen: Die KI-Aktie, die seit der Integration von Deepseek R1 Wellen schlägt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PD78 | ISIN: BE0974340722 | Ticker-Symbol: 2SE
Frankfurt
21.02.25
08:07 Uhr
1,515 Euro
-0,015
-0,98 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
SEQUANA MEDICAL NV Chart 1 Jahr
5-Tage-Chart
SEQUANA MEDICAL NV 5-Tage-Chart
RealtimeGeldBriefZeit
1,5351,63522.02.

Aktuelle News zur SEQUANA MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.02.Sequana Medical NV: Press Release: Transparency Notification from Shareholders236Transparency Notification from Shareholders Ghent, Belgium - 10 February 2025 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment...
► Artikel lesen
03.02.Sequana Medical NV: Transparency Notifications from Shareholders338Transparency Notifications from Shareholders Ghent, Belgium - 3 February 2025 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment...
► Artikel lesen
24.01.Sequana Medical NV: Press release: Sequana Medical Announces New Share Capital Amount and New Number of Shares following Loan Conversions485SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES FOLLOWING LOAN CONVERSIONS Conversion of EUR 0.53 million under the Sensinnovat 2020 loan, EUR 1.28 million under...
► Artikel lesen
SEQUANA MEDICAL Aktie jetzt für 0€ handeln
13.01.Sequana Medical NV: Press release: Transparency Notification from Shareholders335Transparency Notification from Shareholders Ghent, Belgium - 13 January 2025 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment...
► Artikel lesen
07.01.Sequana Medical NV: Press release: Six Month Data from alfapump Pivotal POSEIDON Study in Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis Published in American Journal of Gastroenterology1.371Six Month Data from alfapump® Pivotal POSEIDON Study in Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis Published in American Journal of Gastroenterology alfapump® system is...
► Artikel lesen
06.01.Sequana Medical NV: Press release: Sequana Medical Announces Key Opinion Leader (KOL) Webinar to Discuss alfapump US Commercial Roll-Out on January 8th at 15:00 CET / 09:00 EST428Sequana Medical Announces Key Opinion Leader (KOL) Webinar to Discuss alfapump® US Commercial Roll-Out on January 8th at 15:00 CET / 09:00 EST Webinar to discuss US commercial roll-out following...
► Artikel lesen
03.01.FDA approves Sequana Medical's Alfapump for ascites treatment2
23.12.24Sequana Medical: FDA Approves Alfapump For Treatment Of R/R Ascites Due To Liver Cirrhosis16
23.12.24Sequana Medical NV: Press release: Sequana Medical Announces US FDA Approval of alfapump for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis693Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis alfapump® is the first US approved active implantable medical device...
► Artikel lesen
20.12.24Sequana Medical NV: Press Release: Sequana Medical announces results of Extraordinary General Meeting of Shareholders and update on Convertible Financing431Sequana Medical announces results of Extraordinary General Meeting of Shareholders and update on Convertible Financing Ghent, Belgium - 20 December 2024 - Sequana Medical NV (Euronext Brussels:...
► Artikel lesen
06.12.24Sequana Medical NV: Press Release: Sequana Medical announces decision of major shareholders to invest in Second Tranche of Convertible Bridge Loan351SEQUANA MEDICAL ANNOUNCES DECISION OF MAJOR SHAREHOLDERS TO INVEST IN SECOND TRANCHE OF CONVERTIBLE BRIDGE LOAN Ghent, Belgium, 6 December 2024 - Sequana Medical NVand here). For more information...
► Artikel lesen
02.12.24Sequana Medical NV: Press Release: Sequana Medical announces update on second tranche of convertible bridge loan189SEQUANA MEDICAL ANNOUNCES UPDATE ON SECOND TRANCHE OF CONVERTIBLE BRIDGE LOAN Ghent, Belgium - 2 December 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical")...
► Artikel lesen
27.11.24Sequana Medical NV: Press Release: Publication in Kidney Medicine Highlights Benefits of DSR 2.0 for Sequana Medical's Direct Sodium Removal Heart Failure Program and Board Composition Update558Publication in Kidney Medicine Highlights Benefits of DSR 2.0 for Sequana Medical's Direct Sodium Removal Heart Failure Program and Board Composition Update More efficient sodium and fluid removal...
► Artikel lesen
26.11.24Sequana Medical NV: Press Release: Transparency Notification from Shareholders374Transparency Notification from Shareholders Ghent, Belgium - 26 November 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment...
► Artikel lesen
20.11.24Sequana Medical NV: Press Release: Sequana Medical announces Extraordinary General Meeting of Shareholders on 20 December 2024484Sequana Medical announces Extraordinary General Meeting of Shareholders on 20 December 2024 Ghent, Belgium - 20 November 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company"...
► Artikel lesen
18.11.24Sequana Medical NV: Press Release: Sequana Medical Announces Strong 24-Month Results from POSEIDON Study at AASLD The Liver Meeting in San Diego; US PMA alfapump approval expected before end of Q1 2025310Sequana Medical Announces Strong 24-Month Results from POSEIDON Study at AASLD The Liver Meeting® in San Diego; US PMA alfapump approval expected before end of Q1 2025 alfapump was very effective...
► Artikel lesen
14.11.24Sequana Medical NV: Press Release: Sequana Medical Announces New Share Capital Amount and New Number of Shares243SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES Ghent, Belgium, 14 November 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical")...
► Artikel lesen
23.10.24Sequana Medical NV: Press release: SEQUANA MEDICAL ANNOUNCES ADDITIONAL CONVERTIBLE FINANCING OF UP TO EUR 1.0 MILLION FROM EXISTING INVESTORS422SEQUANA MEDICAL ANNOUNCES ADDITIONAL CONVERTIBLE FINANCING OF UP TO EUR 1.0 MILLION FROM EXISTING INVESTORS Ghent, Belgium, 23 October 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company"...
► Artikel lesen
21.10.24Sequana Medical NV: Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES276PRESS RELEASEREGULATED INFORMATION21 October 2024, 06:00 p.m. CEST SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES Ghent, Belgium, 21 October 2024 - Sequana Medical...
► Artikel lesen
10.10.24Sequana Medical NV: Press release: Transparency Notification from Shareholders371Transparency Notification from Shareholders Ghent, Belgium - 10 October 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment...
► Artikel lesen
Seite:  Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1